Early identification of CKD through screening, followed by accurate diagnosis and staging to inform the best treatment, offers the potential to significantly reduce the morbidity and mortality of this burdensome disease and its complications.
Using evidence-based algorithms and classification tools, this interactive eLearning will guide you through the steps to reach an early and accurate diagnosis, as well as initial management guidance and when to make a referral.
The slides and audio are in English with transcripts available in French, German, Italian, Japanese, Portuguese (European), Spanish (European), and Chinese (simplified). Please log in to select your preferred language.
This eLearning activity has been endorsed by KDIGO and PCDE.
Professor David Wheeler
David Wheeler is Professor of Kidney Medicine at University College London, UK, and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust. He is a clinician scientist interested in the complications of chronic kidney disease, specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated in the development and running of several large-scale clinical trials testing lipid-lowering regimens, calcimimetics, SGLT2 inhibitors and HIF stabilisers in patients with chronic kidney disease.
Professor Wheeler’s other roles include Honorary Professorial Fellow of The George Institute and Chair of the International Society of Nephrology Advancing Clinical Trials network. He has been involved in the development of Clinical Practice Guidelines for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO). He served as KDIGO co-chair between 2012 and 2019. In the UK, he is National Institute of Health Research (NIHR) Renal Specialty Lead and Co-Medical Director of the North Thames NIHR Clinical Research Network.
David Wheeler discloses the following interests: Ongoing consultancy arrangement with AstraZeneca. Honoraria from Amgen, Astellas, Bayer, Boehringer Ingelheim, GSK, Janssen, Napp, Mundipharma, and MSD.
Dr Kevin Fernando
Kevin Fernando is a part-time GP Partner and GP Educational Supervisor at the North Berwick Health Centre, North Berwick, UK. He is also Scottish lead of the Primary Care Diabetes Society. His other roles include RCGP Clinical Advisor for Diabetes & Multimorbidity and Education Director for GPnotebook Education.
Dr Fernando graduated from the University of Edinburgh, Edinburgh, UK in 2000 and holds both MRCGP and MRCP (UK) qualifications and has completed a master’s degree in diabetes, which he passed with distinction.
Dr Fernando has been elected to the Fellowship of the Royal College of General Practitioners, the Royal College of Physicians of Edinburgh, and the Academy of Medical Educators for his work in diabetes and medical education.
Kevin Fernando discloses financial or/and non-financial relationship with AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Lilly, MSD, Novo Nordisk, OmniaMed, Roche, Pfizer, Napp, Mundipharma, Amgen, and Sanofi.